IKBKG and neoplasm: IP treatment of SKOV3-Luc-IP1 tumor-bearing mice showed an increase in median survival (from 33 days in the control group to 90 days in the treated mice), with a clear reduction in tumor burden, PCI score and ascitic fluid production (140).